Research

Publications
Title: Interactions between intestinal microbiota and metabolites in zebrafish larvae exposed to polystyrene nanoplastics: Implications for intestinal health and glycolipid metabolism
First author: Zhu, Biran; Chen, Xianglin; Zhang, Taotao; Zhang, Qianqian; Fu, Kaiyu; Hua, Jianghuan; Zhang, Mengyuan; Qi, Qing; Zhao, Binbin; Zhao, Min; Yang, Lihua; Zhou, Bingsheng
Journal: JOURNAL OF HAZARDOUS MATERIALS
Years: 2024
Volume / issue: /
DOI: 10.1016/j.jhazmat.2024.134478
Abstract: Previous studies have shown the harmful effects of nanoscale particles on the intestinal tracts of organisms. However, the specific mechanisms remain unclear. Our present study focused on examining the uptake and distribution of polystyrene nanoplastics (PS -NPs) in zebrafish larvae, as well as its toxic effects on the intestine. It was found that PS -NPs, marked with red fluorescence, primarily accumulated in the intestine section. Subsequently, zebrafish larvae were exposed to normal PS -NPs (0.2 -25 mg/L) over a critical 10 -day period for intestinal development. Histopathological analysis demonstrated that PS -NPs caused structural changes in the intestine, resulting in inflammation and oxidative stress. Additionally, PS -NPs disrupted the composition of the intestinal microbiota, leading to alterations in the abundance of bacterial genera such as Pseudomonas a nd Aeromonas , which are associated with intestinal inflammation. Metabolomics analysis showed alterations in metabolites that are primarily involved in glycolipid metabolism. Furthermore, MetOrigin analysis showed a significant correlation between bacterial flora ( Pedobacter and Bacillus ) and metabolites (D-Glycerate 2 -phosphate and D-Glyceraldehyde 3 -phosphate), which are related to the glycolysis/gluconeogenesis pathways. These findings were further validated through alterations in multiple biomarkers at various levels. Collectively, our data suggest that PS -NPs may impair the intestinal health, disrupt the intestinal microbiota, and subsequently cause metabolic disorders.